DHR vs MRVI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

DHR is the larger of the two ($157.25B market cap): the incumbent the market prices for continued execution (23.98x forward earnings, beta 0.80). MRVI is the smaller challenger ($1.83B), still expected to post a loss next year: more room to run, but more to prove. If the story you believe is DHR's (Bioprocessing recovery), DHR is the more direct way to own it; if it is MRVI's (TriLink base mRNA demand outside COVID), MRVI is.

DHR vs MRVI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDHRMRVIWhat it tells you
Market cap$157.25B$1.83BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E23.98-93.03Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.800.63Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range64% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.935.37How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how DHR and MRVI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and MRVI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and MRVI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Danaher Corporation (DHR) do?

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

What does Maravai LifeSciences (MRVI) do?

Maravai LifeSciences is a San Diego life sciences tools company that GTCR controls. It runs two businesses. The larger is TriLink BioTechnologies, which makes the nucleic acid building blocks behind mRNA medicines: CleanCap capping reagents, modified nucleotides, enzymes, DNA templates and custom mRNA, sold for research and in GMP grade for clinical and commercial production. The second is Cygnus Technologies. It sells host cell protein (HCP) detection kits, ELISA assays and related services, which biologics manufacturers use to show regulators that impurities have been removed from their drugs. In 2021 and 2022, CleanCap orders tied to COVID vaccines pushed revenue close to $900M. When those orders went away, revenue fell to about $186M in 2025, along with large losses, goodwill writedowns and layoffs.

Full MRVI guide

DHR vs MRVI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
  • MRVI drivers: TriLink base mRNA demand outside COVID; Margin repair and operating leverage.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. For MRVI, valuation is the first risk.

DHR or MRVI: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate DHR from MRVI. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and MRVI guides.

DHR vs MRVI: the full fundamentals

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026 and about 8.3% in the third. The stock trades near 24x forward earnings and about 22x EV/EBITDA as of November 20, 2026, within its usual premium range, with consensus EPS of about $8.59 for 2026 and $9.32 for 2027. The 21 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $260, about 16% above the latest close; figures are approximate.

MRVI. The market cap above counts all ~260M Class A shares and exchangeable Class B units at about $7.03, which matches the figure Yahoo Finance shows. Adding ~$226M of debt and subtracting ~$73M of cash gives an enterprise value near $2.0B, about 9x trailing sales and roughly 48x the midpoint of the raised adjusted EBITDA guidance, still well above many slower-growth life sciences tools peers. GAAP results are still loss-making (a ~$24.0M Q3 net loss), so investors are valuing adjusted EBITDA and its direction. Seven analysts tracked by Yahoo Finance carry a mean target near $9.64.

Headline figures (approximate, November 2026): DHR shows revenue (ttm) ~$25.6B; Q3 2026 ~$6.55B (+8.3%), q3 2026 adj. eps $2.11 vs ~$1.92 estimate, margins (ttm) ~59.4% gross, ~22.0% operating, ~16.9% net, net income (ttm) ~$4.29B (GAAP EPS ~$6.04); MRVI shows revenue (ttm) ~$213M (Q3 2026 +10% YoY), 2026 revenue guidance ~$212M to $216M (raised from $205M to $215M), 2026 adj. ebitda guidance ~$40M to $42M (raised from $33M to $35M), q3 2026 adj. eps -$0.03 vs ~-$0.06 consensus.

The bottom line: DHR vs MRVI

DHR and MRVI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DHR and MRVI exposure against your real portfolio. It is not an investment adviser.

Wondering how DHR or MRVI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Danaher Corporation

Ask Walnut's AI anything about DHR and see how it fits what you own.

FAQ

What is the difference between DHR and MRVI?

+

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). Maravai LifeSciences is a San Diego life sciences tools company that GTCR controls. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DHR or MRVI the better stock?

+

Neither is universally better. DHR is the larger incumbent; MRVI is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DHR or MRVI?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DHR and MRVI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DHR vs MRVI?

+

DHR: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. Core revenue growth has been slow, around 2% for 2025 and roughly flat in early 2026, so the thesis leans heavily on the bioprocessing recovery arriving on schedule. Biopharma and academic funding cycles, hospital and diagnostics testing volumes, and currency swings all move results. China demand and policy, along with broader biotech funding conditions, are additional swing factors. As a diversified conglomerate, weakness in any one segment can offset strength elsewhere. The shares gave back ground after the third-quarter beat, which shows that strong prints are already expected at this valuation. Total debt of about $27.8 billion against about $5.7 billion of cash is manageable for a company of this size but limits how large the next acquisition can be without more borrowing. MRVI: Valuation is the first risk. At about $7.03, MRVI trades near 9x trailing sales of ~$213M and more than 40x the midpoint of the raised 2026 adjusted EBITDA guidance, which leaves little room for a weak quarter; consensus also has 2027 revenue only about 5% above 2026 guidance. Revenue is concentrated: Pfizer accounted for ~12% of first-half revenue, and a single vaccine customer accounted for ~18% of receivables at mid-year. Management has said it does not expect more high-volume COVID orders in 2026, and Q2 COVID CleanCap revenue was zero, so the year-over-year comparison gets harder. Cash fell from ~$217M at year-end 2025 to ~$70M at June 30, 2026, mostly because the company used cash to repay debt, leaving a $150M term loan due 2032; Yahoo Finance shows ~$73M of cash and ~$226M of total debt after Q3. Wider mRNA sentiment, including US policy pullbacks on mRNA vaccine funding, can hit research budgets. Competition from Thermo Fisher, Danaher's Aldevron and low-cost Chinese suppliers could pressure CleanCap pricing as patents age. GTCR controls the majority of voting power, so outside shareholders have limited influence, and future GTCR sales could add supply. The stock moves sharply in both directions: it fell about 22% over the three months to November 20, 2026 even as guidance rose.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DHR or MRVI; figures are approximate and dated (as of November 2026). Verify current data before investing.